OptimizeRx’s (OPRX) Buy Rating Reiterated at B. Riley Financial

B. Riley Financial restated their buy rating on shares of OptimizeRx (NASDAQ:OPRX – Free Report) in a report released on Thursday morning,Benzinga reports. B. Riley Financial currently has a $10.50 target price on the stock, down from their prior target price of $11.00.

A number of other research analysts also recently commented on the stock. Citigroup reaffirmed a “market outperform” rating on shares of OptimizeRx in a research report on Tuesday, October 27th. Wall Street Zen downgraded shares of OptimizeRx from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 20th. Citizens Jmp increased their target price on shares of OptimizeRx from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research report on Friday, August 14th. UBS Group set a $11.00 target price on shares of OptimizeRx in a research note on Friday, August 14th. Finally, Weiss Ratings upgraded shares of OptimizeRx from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, August 25th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, OptimizeRx currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.21.

Check Out Our Latest Research Report on OptimizeRx

OptimizeRx Stock Down 17.2%

NASDAQ:OPRX traded down $1.53 on Thursday, hitting $7.34. 611,439 shares of the company’s stock traded hands, compared to its average volume of 210,704. The company has a current ratio of 5.06, a quick ratio of 5.58 and a debt-to-equity ratio of 0.09. OptimizeRx has a 1 year low of $4.54 and a 1 year high of $15.59. The firm has a 50-day moving average price of $8.43 and a 200-day moving average price of $7.20. The company has a market cap of $138.29 million, a PE ratio of 29.36 and a beta of 1.20.

OptimizeRx (NASDAQ:OPRX – Get Free Report) last issued its earnings results on Wednesday, November 11th. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.04. The company had revenue of $21.61 million for the quarter, compared to the consensus estimate of $21.19 million. OptimizeRx had a return on equity of 9.58% and a net margin of 5.33%. Equities analysts anticipate that OptimizeRx will post 0.49 EPS for the current fiscal year.

Institutional Trading of OptimizeRx

A number of institutional investors and hedge funds have recently modified their holdings of the company. Royce & Associates LP boosted its holdings in shares of OptimizeRx by 20.7% during the 3rd quarter. Royce & Associates LP now owns 1,315,057 shares of the company’s stock worth $10,981,000 after buying an additional 225,659 shares during the period. Marshall Wace LLP grew its stake in OptimizeRx by 183.2% in the 3rd quarter. Marshall Wace LLP now owns 459,362 shares of the company’s stock valued at $3,836,000 after buying an additional 297,176 shares during the last quarter. Rice Hall James & Associates LLC grew its stake in OptimizeRx by 1.9% in the 1st quarter. Rice Hall James & Associates LLC now owns 601,921 shares of the company’s stock valued at $3,780,000 after buying an additional 11,247 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in OptimizeRx by 22.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 563,570 shares of the company’s stock worth $3,540,000 after acquiring an additional 102,661 shares during the period. Finally, Tocqueville Asset Management L.P. bought a new position in OptimizeRx in the 3rd quarter worth $1,670,000. 76.47% of the stock is currently owned by institutional investors and hedge funds.

About OptimizeRx

(Get Free Report)

OptimizeRx is a healthcare technology company that connects life sciences companies with healthcare professionals and patients through digital communications. Its platform uses channels such as electronic health records and other clinical workflows to deliver relevant information at the point of care. The company’s services support programs for medication access and affordability, patient education and engagement, and communication between healthcare providers and life sciences organizations. OptimizeRx also provides tools intended to help life sciences companies reach clinicians and patients through digital channels.

Further Reading

Analyst Recommendations for OptimizeRx (NASDAQ:OPRX)

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.